NCT02475278View on ClinicalTrials.gov

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 26, 2015

Primary Completion Date

April 7, 2015

Study Completion Date

September 9, 2015

Conditions
NorovirusHealthy Participants
Interventions
BIOLOGICAL

NoV GI.1/GII.4 Bivalent VLP Vaccine

Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection

Trial Locations (1)

78705

Benchmark Research Austin, Austin

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY